Abeona Therapeutics Reports Progress on ZEVASKYN Launch, Revenue Growth
Abeona Therapeutics (NASDAQ:ABEO) highlighted strong progress in its commercial launch of ZEVASKYN during the H.C. Wainwright conference. The company reported $11.4 million in quarterly net product revenue, a sequential increase of 31%, and had treated 12 patients across seven qualified centers as of August 13, 2026. ZEVASKYN is an autologous gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB). Abeona has secured coverage in over 95% of commercial lives and Medicaid across all U.S. states but faces administrative challenges such as prior authorizations and single-case agreements, which slow treatment timelines. The company estimates approximately 750 eligible patients in the U.S., with ZEVASKYN priced at $3.1 million per cycle. Abeona holds $146 million in cash to support its launch efforts and future development programs.
Tickers: $ABEO